As founding Partner and Chief Investment Officer, Mr. Tunnicliffe has extensive experience in the global pharmaceutical industry and over 30 years of overall experience in investing and finance. He is responsible for the investment activity of NovaQuest’s Product Finance investments and he is also a member of the Product Finance investment committees. Mr. Tunnicliffe’s experience has included investments across the global pharmaceutical industry that covered a broad range of therapeutic areas and investment structures.
From the formation of the NovaQuest unit at Quintiles (IQVIA) in 2000 through 2010, Mr. Tunnicliffe built and led the due diligence for product-based and company investments. These transactions were with both private and leading public biopharmaceutical companies. Mr. Tunnicliffe was previously a founding member and Director of Operations for a specialized clinical research organization, S-Cubed, where he led all operational functions. In Mr. Tunnicliffe’s earlier career, he was a medical statistician at SmithKline and French (now Glaxo SmithKline) and at the University of Sheffield
Mr. Tunnicliffe has a BSc (Hons) in Mathematical Statistics from the University of Liverpool, an MSc in Medical Statistics from the University of Newcastle-upon-Tyne and an MBA from Sheffield Hallam University.